India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's patent office will hold hearings Feb. 28 and 29 to decide whether India's Natco Pharmaceuticals should be awarded the country's first compulsory license to make and export to Nepal generic cancer drugs patented locally by Roche and Pfizer
You may also be interested in...
Indian Court Restrains Cipla From Exporting Generic Tarceva
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said
Indian Court Restrains Cipla From Exporting Generic Tarceva
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)
Need a specific report? 1000+ reports available
Buy Reports